Comparable stake leader
Capital World Investors
SEC ownership of VERTEX PHARMACEUTICALS INC / MA
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000875320.
Disclosed value leader
Capital World Investors
Comparable rows
50/50
Latest evidence
21 Jul 2026
- Public ticker
- VRTX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Capital World Investors
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Capital World Investors
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
21 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000875320
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of VERTEX PHARMACEUTICALS INC / MA (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Capital World Investors
Disclosed value leader
Capital World Investors
Comparable rows
50/50
Latest evidence
21 Jul 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: Capital World Investors
Showing 1-8 of 50 holder rows.
Quick read
Capital World Investors leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Capital World Investors's linked filing trail.
Comparable ownership
Top 5
Capital World Investors
10%
Capital Research Global Investors
8.3%
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
FMR LLC
3.6%
Reshma Kewalramani
0.04%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Capital World Investors |
13F
13D/G
Company
|
10%
from 13D/G
|
$12,972,221,775
26,115,014 shares
|
— | 30 Jun 2026 |
| Capital Research Global Investors |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$9,681,703,171
19,490,637 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
7.5%
|
$8,500,369,377
19,036,076 shares
|
$0 | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
3.6%
|
$4,642,686,284
9,220,827 shares
|
$0 | 31 Dec 2024 |
| Reshma Kewalramani |
3/4/5
CEO & President, Director
|
0.04%
|
$48,839,252
98,278 shares
|
-$19,738,855 | 27 Feb 2026 |
| Amit Sachdev |
3/4/5
EVP Chief Patient & Ext Af Off
|
0.03%
|
$36,773,417
74,031 shares
|
-$28,377,385 | 21 Jul 2026 |
| Stuart A. Arbuckle |
3/4/5
EVP, COO
|
0.02%
|
$28,594,582
63,508 shares
|
— | 01 Jul 2025 |
| Ourania Tatsis |
3/4/5
EVP, Chief Reg. & Quality Off.
|
0.02%
|
$26,610,819
53,572 shares
|
-$6,513,287 | 21 Jul 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$158,378,024.
Buys
$0
Insiders: 0
Sells
$158,378,024
Insiders: 13
Net
-$158,378,024
Shares: -343,058
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 343,058
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 14,094 | $0 | $6,628,187 | -$6,628,187 |
| 3-6 | 0 | 21,395 | $0 | $9,902,185 | -$9,902,185 |
| 6-9 | 0 | 231,083 | $0 | $108,188,360 | -$108,188,360 |
| 9-12 | 0 | 76,486 | $0 | $33,659,292 | -$33,659,292 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to VERTEX PHARMACEUTICALS INC / MA. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Reshma Kewalramani
Net 12M change
-$158,378,025
Latest report
21 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Reshma Kewalramani | CEO & President, Director | $48,839,252 | -$19,738,855 | -29% | Filing P/S | 27 Feb 2026 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | $36,773,417 | -$28,377,385 | -44% | Median | 21 Jul 2026 |
| Stuart A. Arbuckle | Evp, Coo | $28,594,582 | Mixed | 01 Jul 2025 | ||
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | $26,610,819 | -$6,513,287 | -20% | Median | 21 Jul 2026 |
| Bruce I. Sachs | Director | $24,446,598 | Mixed | 15 Jul 2026 | ||
| Charles F. Wagner Jr. | Evp, Co & Fo | $22,820,544 | -$10,778,252 | -32% | Mixed | 24 Feb 2026 |
| Jeffrey M. Leiden | Executive Chairman, Director | $17,073,496 | -$60,942,657 | -78% | Mixed | 24 Feb 2026 |
| David Altshuler | EVP, Chief Scientific Officer | $15,630,492 | Mixed | 22 Jan 2026 | ||
| Bastiano Sanna | EVP, Cell & Genetic Therapies | $13,426,165 | Mixed | 05 May 2023 | ||
| Joy Liu | EVP and Chief Legal Officer | $9,617,345 | -$2,131,396 | -18% | Filing P/S | 01 Jul 2026 |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | $8,964,403 | -$3,598,635 | -29% | Filing P/S | 24 Feb 2026 |
| Carmen Bozic | EVP and CMO | $7,400,102 | -$11,309,998 | -60% | Filing P/S | 26 Jun 2026 |
| Jonathan Biller | EVP and Chief Legal Officer | $6,643,054 | -$4,076,426 | -38% | Filing P/S | 24 Feb 2026 |
| Duncan McKechnie | EVP, Chief Commercial Officer | $5,709,519 | -$5,664,790 | -50% | Filing P/S | 02 Jul 2026 |
| Diana Mckenzie | Director | $3,568,170 | Mixed | 01 May 2026 | ||
| Alan M. Garber | Director | $3,535,588 | Mixed | 15 Jul 2026 | ||
| Mark E. Bunnage | EVP, Chief Scientific Officer | $3,302,929 | -$2,999,734 | -48% | Filing P/S | 15 May 2026 |
| Kristen Ambrose | SVP & Chief Accounting Officer | $3,201,776 | -$1,978,864 | -38% | Filing P/S | 26 Feb 2026 |
| Terrence C. Kearney | Director | $2,995,241 | Mixed | 01 May 2024 | ||
| Lloyd Carney | Director | $2,632,155 | Mixed | 01 May 2026 |
Recent insider transactions for VERTEX PHARMACEUTICALS INC / MA
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ourania Tatsis | VRTX | Common Stock | Award | 18.2% | 8,251 | 53,572 | 21 Jul 2026 | Direct | ||
| Amit Sachdev | VRTX | Common Stock | Award | 14.2% | 8,251 | 66,512 | 21 Jul 2026 | Direct | ||
| Bruce I. Sachs | VRTX | Deferred Stock Units | Award | 0.64% | 99.94 | 15,772 | 15 Jul 2026 | Direct | ||
| Alan M. Garber | VRTX | Deferred Stock Units | Award | 93.1% | 31.56 | 65 | 15 Jul 2026 | Direct | ||
| Ourania Tatsis | VRTX | Common Stock | Sale | -3.2% | $787,485 | $524.99 | -1,500 | 45,321 | 02 Jul 2026 | Direct |
| Duncan McKechnie | VRTX | Common Stock | Sale | -12.3% | $799,779 | $519.00 | -1,541 | 11,001 | 02 Jul 2026 | Direct |
| Joy Liu | VRTX | Common Stock | Sale | -4.15% | $416,244 | $502.71 | -828 | 19,131 | 01 Jul 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -3.74% | $287,570 | $482.50 | -596 | 15,337 | 26 Jun 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -6.02% | $471,413 | $462.17 | -1,020 | 15,933 | 18 Jun 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -19.3% | $1,827,900 | $450.00 | -4,062 | 16,953 | 15 Jun 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -7.67% | $785,250 | $450.00 | -1,745 | 21,015 | 05 Jun 2026 | Direct |
| Joy Liu | VRTX | Common Stock | Sale | -3.98% | $364,245 | $439.91 | -828 | 19,959 | 01 Jun 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -7.98% | $888,300 | $450.00 | -1,974 | 22,760 | 29 May 2026 | Direct |
| Mark E. Bunnage | VRTX | Common Stock | Sale | -0.45% | $14,964 | $453.45 | -33 | 7,284 | 15 May 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -5.19% | $613,971 | $453.45 | -1,354 | 24,734 | 15 May 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -21.1% | $3,144,600 | $450.00 | -6,988 | 26,088 | 12 May 2026 | Direct |
| Sangeeta N. Bhatia | VRTX | Common Stock | Sale | -6.07% | $134,746 | $423.73 | -318 | 4,924 | 04 May 2026 | Direct |
| Suketu Upadhyay | VRTX | Common Stock | Disposed to Issuer | -33.8% | -796 | 1,558 | 01 May 2026 | Direct | ||
| Suketu Upadhyay | VRTX | Deferred Stock Units | Award | 28.4% | 796 | 3,595 | 01 May 2026 | Direct | ||
| Suketu Upadhyay | VRTX | Stock Option (Right to Buy) | Award | 2,866 | 2,866 | 01 May 2026 | Direct | |||
| Nancy Thornberry | VRTX | Common Stock | Disposed to Issuer | -15.9% | -398 | 2,109 | 01 May 2026 | Direct | ||
| Nancy Thornberry | VRTX | Common Stock | Award | 23.2% | 472 | 2,507 | 01 May 2026 | Direct | ||
| Nancy Thornberry | VRTX | Deferred Stock Units | Award | 398 | 398 | 01 May 2026 | Direct | |||
| Nancy Thornberry | VRTX | Stock Option (Right to Buy) | Award | 1,433 | 1,433 | 01 May 2026 | Direct | |||
| Jennifer Schneider | VRTX | Common Stock | Disposed to Issuer | -36.4% | -796 | 1,394 | 01 May 2026 | Direct | ||
| Jennifer Schneider | VRTX | Common Stock | Award | 27.5% | 472 | 2,190 | 01 May 2026 | Direct | ||
| Jennifer Schneider | VRTX | Deferred Stock Units | Award | 796 | 796 | 01 May 2026 | Direct | |||
| Jennifer Schneider | VRTX | Stock Option (Right to Buy) | Award | 1,433 | 1,433 | 01 May 2026 | Direct | |||
| Bruce I. Sachs | VRTX | Stock Option (Right to Buy) | Award | 2,866 | 2,866 | 01 May 2026 | Direct | |||
| Diana Mckenzie | VRTX | Common Stock | Disposed to Issuer | -25.1% | -796 | 2,378 | 01 May 2026 | Direct | ||
| Diana Mckenzie | VRTX | Common Stock | Award | 42.3% | 943 | 3,174 | 01 May 2026 | Direct | ||
| Diana Mckenzie | VRTX | Deferred Stock Units | Award | 11.4% | 796 | 7,787 | 01 May 2026 | Direct | ||
| Joy Liu | VRTX | Common Stock | Sale | -5.06% | $469,222 | $425.02 | -1,104 | 20,729 | 01 May 2026 | Direct |
| Michel Lagarde | VRTX | Stock Option (Right to Buy) | Award | 2,866 | 2,866 | 01 May 2026 | Direct | |||
| Alan M. Garber | VRTX | Common Stock | Award | 6.87% | 472 | 7,344 | 01 May 2026 | Direct | ||
| Alan M. Garber | VRTX | Stock Option (Right to Buy) | Award | 1,433 | 1,433 | 01 May 2026 | Direct | |||
| Lloyd Carney | VRTX | Stock Option (Right to Buy) | Award | 2,866 | 2,866 | 01 May 2026 | Direct | |||
| Sangeeta N. Bhatia | VRTX | Common Stock | Award | 21.9% | 943 | 5,242 | 01 May 2026 | Direct | ||
| Suketu Upadhyay | VRTX | Deferred Stock Units | Award | 2.96% | 80.51 | 2,799 | 15 Apr 2026 | Direct | ||
| Bruce I. Sachs | VRTX | Deferred Stock Units | Award | 0.69% | 107 | 15,672 | 15 Apr 2026 | Direct | ||
| Alan M. Garber | VRTX | Deferred Stock Units | Award | 33.9 | 34 | 15 Apr 2026 | Direct | |||
| Joy Liu | VRTX | Common Stock | Sale | -4.29% | $439,288 | $449.17 | -978 | 21,833 | 01 Apr 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -6.58% | $1,050,263 | $450.95 | -2,329 | 33,076 | 27 Mar 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -6.17% | $1,122,089 | $481.79 | -2,329 | 35,405 | 13 Mar 2026 | Direct |
| Duncan McKechnie | VRTX | Common Stock | Sale | -17.4% | $1,312,340 | $498.42 | -2,633 | 12,489 | 11 Mar 2026 | Direct |
| Duncan McKechnie | VRTX | Common Stock | Sale | -13.9% | $1,158,306 | $475.30 | -2,437 | 15,122 | 04 Mar 2026 | Direct |
| Joy Liu | VRTX | Common Stock | Sale | -3.76% | $442,396 | $495.96 | -892 | 22,811 | 02 Mar 2026 | Direct |
| Reshma Kewalramani | VRTX | Common Stock | Sale | -28.9% | $19,738,855 | $493.47 | -40,000 | 98,278 | 27 Feb 2026 | Direct |
| Carmen Bozic | VRTX | Common Stock | Sale | -5.81% | $1,118,642 | $480.31 | -2,329 | 37,734 | 27 Feb 2026 | Direct |
| Kristen Ambrose | VRTX | Common Stock | Sale | -5.11% | $172,560 | $483.36 | -357 | 6,624 | 26 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.